Loading...

GT Biopharma

ENXTPA:GTBP
Snowflake Description

Imperfect balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GTBP
ENXTPA
$21M
Market Cap
  1. Home
  2. FR
  3. Pharmaceuticals & Biotech
Company description

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based off its proprietary technology platforms. The last earnings update was 101 days ago. More info.


Add to Portfolio Compare Print
  • GT Biopharma has significant price volatility in the past 3 months.
GTBP Share Price and Events
7 Day Returns
0%
ENXTPA:GTBP
-3%
FR Biotechs
1.2%
FR Market
1 Year Returns
-
ENXTPA:GTBP
-36.3%
FR Biotechs
-0.9%
FR Market
GTBP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
GT Biopharma (GTBP) 0% 0% -34% - -99.9% -99.9%
FR Biotechs -3% 0.8% -15.2% -36.3% -50.2% -51.9%
FR Market 1.2% 7.1% 5.7% -0.9% 27.1% 26%
1 Year Return vs Industry and Market
  • No trading data on GTBP.
  • No trading data on GTBP.
Price Volatility
GTBP
Industry
5yr Volatility vs Market
Related Companies

Value

 Is GT Biopharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of GT Biopharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data    Our calculation method for this is changing soon.

Below are the data sources, inputs and calculation used to determine the intrinsic value for GT Biopharma.

ENXTPA:GTBP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 16.7%
Perpetual Growth Rate 10-Year FR Government Bond Rate 0.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ENXTPA:GTBP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year FR Govt Bond Rate 0.7%
Equity Risk Premium S&P Global 9.3%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.24
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.241 (1 + (1- 21%) (49.71%))
1.728
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.73
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.73% + (1.728 * 9.27%)
16.75%

Discounted Cash Flow Calculation for ENXTPA:GTBP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for GT Biopharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

ENXTPA:GTBP DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (USD, Millions) 0.75 0.61 0.50 0.41 0.35
Source Est @ -20%, capped from -107.86% Est @ -19%, capped from -107.86% Est @ -18%, capped from -107.86% Est @ -17%, capped from -107.86% Est @ -16%, capped from -107.86%
Present Value
Discounted (@ 16.75%)
0.64 0.45 0.31 0.22 0.16
Present value of next 5 years cash flows $1.79
ENXTPA:GTBP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= $0.35 × (1 + 0.73%) ÷ (16.75% – 0.73%)
$2.19
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= $2.19 ÷ (1 + 16.75%)5
$1.01
ENXTPA:GTBP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= $1.79 + $1.01
$2.80
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2.80 / 50.90
$0.13
ENXTPA:GTBP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in ENXTPA:GTBP represents 2.45236x of OTCPK:GTBP
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
2.45236x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 0.05 x 2.45236
€0.13
Value per share (EUR) From above. €0.13
Current discount Discount to share price of €1.03
= -1 x (€1.03 - €0.13) / €0.13
-664.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of GT Biopharma is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for GT Biopharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are GT Biopharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:GTBP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-5.19
OTCPK:GTBP Share Price ** OTCPK (2018-12-04) in USD $0.42
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 23.17x
France Market PE Ratio Median Figure of 416 Publicly-Listed Companies 15.32x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of GT Biopharma.

ENXTPA:GTBP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:GTBP Share Price ÷ EPS (both in USD)

= 0.42 ÷ -5.19

-0.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GT Biopharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • GT Biopharma is loss making, we can't compare the value of its earnings to the France market.
Price based on expected Growth
Does GT Biopharma's expected growth come at a high price?
Raw Data
ENXTPA:GTBP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.08x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 21 Publicly-Listed Biotechs Companies 1.74x
France Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.33x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for GT Biopharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on GT Biopharma's assets?
Raw Data
ENXTPA:GTBP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $0.27
OTCPK:GTBP Share Price * OTCPK (2018-12-04) in USD $0.42
France Biotechs Industry PB Ratio Median Figure of 32 Publicly-Listed Biotechs Companies 1.96x
France Market PB Ratio Median Figure of 617 Publicly-Listed Companies 1.51x
ENXTPA:GTBP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:GTBP Share Price ÷ Book Value per Share (both in USD)

= 0.42 ÷ 0.27

1.56x

* Primary Listing of GT Biopharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GT Biopharma is good value based on assets compared to the FR Biotechs industry average.
X
Value checks
We assess GT Biopharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. GT Biopharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is GT Biopharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GT Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.7%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is GT Biopharma expected to grow at an attractive rate?
  • Unable to compare GT Biopharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare GT Biopharma's earnings growth to the France market average as no estimate data is available.
  • Unable to compare GT Biopharma's revenue growth to the France market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ENXTPA:GTBP Future Growth Rates Data Sources
Data Point Source Value (per year)
France Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 20.7%
France Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 30.6%
France Market Earnings Growth Rate Market Cap Weighted Average 12.6%
France Market Revenue Growth Rate Market Cap Weighted Average 4.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:GTBP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:GTBP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 -12 -260
2018-06-30 -10 -155
2018-03-31 -9 -148
2017-12-31 -5 -143
2017-09-30 -3 -141
2017-06-30 -2 -14
2017-03-31 -2 -10
2016-12-31 -2 10
2016-09-30 0 -3 -14
2016-06-30 0 -3 -12
2016-03-31 0 -3 14
2015-12-31 0 -5 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if GT Biopharma is high growth as no earnings estimate data is available.
  • Unable to determine if GT Biopharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:GTBP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from GT Biopharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:GTBP Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -5.19
2018-06-30 -3.72
2018-03-31 -5.07
2017-12-31 -8.54
2017-09-30 -33.20
2017-06-30 -64.95
2017-03-31 -86.80
2016-12-31 119.91
2016-09-30 -230.48
2016-06-30 -305.01
2016-03-31 669.87
2015-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if GT Biopharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of GTBP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. GT Biopharma's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. GT Biopharma's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess GT Biopharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
GT Biopharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has GT Biopharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare GT Biopharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • GT Biopharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare GT Biopharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare GT Biopharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
GT Biopharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from GT Biopharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:GTBP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 -260.06 16.36 7.99
2018-06-30 -154.90 137.66 7.41
2018-03-31 -148.28 136.80 4.40
2017-12-31 -143.25 134.50 1.07
2017-09-30 -140.98 129.34 1.16
2017-06-30 -13.98 5.29 0.89
2017-03-31 -9.97 6.12 0.89
2016-12-31 9.77 8.40 0.98
2016-09-30 0.00 -13.52 10.21 1.25
2016-06-30 0.00 -11.58 10.48 1.23
2016-03-31 0.02 13.74 10.06 0.98
2015-12-31 0.03 -21.46 7.95 1.00
2015-09-30 0.06 -13.98 7.21 0.48
2015-06-30 0.06 -16.51 5.21 0.25
2015-03-31 0.07 -43.63 3.87 0.25
2014-12-31 0.06 -23.49 2.40
2014-09-30 0.07 -5.21 1.01
2014-06-30 0.25 -1.30 0.66
2014-03-31 0.28 -1.34 0.67
2013-12-31 0.37 -0.50 0.94
2013-09-30 0.55 -0.91 1.58
2013-06-30 0.48 -2.00 2.82
2013-03-31 0.43 -4.09 3.73
2012-12-31 0.34 -5.17 3.76
2012-09-30 0.13 -5.55 3.95 -0.03
2012-06-30 0.01 -4.13 3.05 -0.03
2012-03-31 0.01 -2.39 2.45 -0.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if GT Biopharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if GT Biopharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if GT Biopharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess GT Biopharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
GT Biopharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is GT Biopharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up GT Biopharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • GT Biopharma's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • GT Biopharma has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of GT Biopharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from GT Biopharma Company Filings, last reported 4 months ago.

ENXTPA:GTBP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 13.31 10.63 1.23
2018-06-30 246.06 6.89 1.10
2018-03-31 252.26 2.96 2.87
2017-12-31 251.69 0.03 0.58
2017-09-30 253.72 0.03 2.73
2017-06-30 -20.08 12.42 0.04
2017-03-31 -18.11 11.79 0.24
2016-12-31 -18.92 12.41 0.02
2016-09-30 -17.21 11.29 0.15
2016-06-30 -15.83 10.60 0.36
2016-03-31 -20.22 10.58 0.03
2015-12-31 -50.57 9.75 0.05
2015-09-30 -24.55 6.10 0.04
2015-06-30 -22.90 4.40 0.13
2015-03-31 -49.93 3.76 1.42
2014-12-31 -29.57 3.36 0.86
2014-09-30 -10.90 3.01 0.66
2014-06-30 -6.97 2.82 0.00
2014-03-31 -6.71 2.73 0.00
2013-12-31 -6.33 2.59 0.04
2013-09-30 -5.97 2.27
2013-06-30 -5.60 2.17 0.01
2013-03-31 -5.29 1.93
2012-12-31 -6.34 1.88 0.12
2012-09-30 -6.24 2.68 0.06
2012-06-30 -6.43 2.21 0.01
2012-03-31 -5.26 2.20 0.12
  • GT Biopharma's level of debt (79.8%) compared to net worth is high (greater than 40%).
  • GT Biopharma had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • GT Biopharma has less than a year of cash runway based on current free cash flow.
  • GT Biopharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 45.8% each year.
X
Financial health checks
We assess GT Biopharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. GT Biopharma has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is GT Biopharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from GT Biopharma dividends.
If you bought €2,000 of GT Biopharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate GT Biopharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate GT Biopharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:GTBP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.9%
France Market Average Dividend Yield Market Cap Weighted Average of 320 Stocks 3.1%
France Minimum Threshold Dividend Yield 10th Percentile 1%
France Bottom 25% Dividend Yield 25th Percentile 1.7%
France Top 25% Dividend Yield 75th Percentile 4.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as GT Biopharma has not reported any payouts.
  • Unable to verify if GT Biopharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of GT Biopharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as GT Biopharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess GT Biopharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can GT Biopharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. GT Biopharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of GT Biopharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ray Urbanski
COMPENSATION $8,766,119
AGE 59
TENURE AS CEO 0.6 years
CEO Bio

Dr. Raymond W. Urbanski, also known as Ray, M.D., Ph.D. has been Chairman of the Board and Chief Executive Officer of GT Biopharma, Inc. since July 3, 2018. He served as Chief Medical Officer at GT Biopharma, Inc. since September 01, 2017 until 2018 and its President since May 14, 2018 until 2018. Dr. Urbanski oversees the development of key products in GT Biopharma's product pipeline, including its platform targeted immunotherapy BiKE and TriKE technologies as well as its newly acquired Central Nervous System pipeline. He served as the Chief Medical Officer of MannKind Corp. since August 10, 2015 until September 29, 2017 and its Corporate Vice President until September 29, 2017. Dr. Urbanski leads MannKind's overall drug development activities and is a member of the Executive Leadership Team. He served as Chief Medical Officer and Senior Director of oncology research and development at Pfizer Inc. (PFE). Dr. Urbanski spent eight years with Pfizer and held several positions with the company, including CMO of the Established Products Business Unit, senior medical director of oncology clinical R&D, senior medical director of breast cancer products and medical director of diversified products. He served as the Vice President and Medical Head of the Established Products Business Unit at Pfizer since 2008 which he built into a global business. From 2004 to 2008, he held various positions in the Pfizer Global Pharmaceutics Group. He has extensive experience in developing and overseeing clinical studies, including phase 3b and phase 4 studies (including line extensions) for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor and tremelimumab. In addition to his role with Pfizer, he served as Chief Medical Officer of Mylan Inc., and Senior Director of US Medical Affairs for Aventis. He served as the Chief Medical Officer at Cymabay Therapeutics, Inc. (alternate name, Metabolex, Inc.) since October 2011. He served as the Vice President for Research and Development at Suntory Pharmaceutical, Inc. from 2001 to 2004 and its CMO. He held various positions at Aventis and AstraZeneca from 1998 to 2001. He has been Director of GT Biopharma, Inc. since July 3, 2018. Dr. Urbanski received his Ph.D. in pharmacology and Toxicology and his M.D. from the University of Medicine and Dentistry of New Jersey.

CEO Compensation
  • Insufficient data for Ray to compare compensation growth.
  • Ray's remuneration is higher than average for companies of similar size in France.
Management Team

Ray Urbanski

TITLE
Chairman & CEO
COMPENSATION
$9M
AGE
59
TENURE
0.6 yrs

Kathleen Clarence-Smith

TITLE
Consultant
COMPENSATION
$500K
AGE
71
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the GT Biopharma board of directors in years:

1.3
Average Tenure
66
Average Age
  • The average tenure for the GT Biopharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ray Urbanski

TITLE
Chairman & CEO
COMPENSATION
$9M
AGE
59
TENURE
0.6 yrs

Tony Cataldo

TITLE
Vice Chairman of the Board
COMPENSATION
$78M
AGE
66
TENURE
0.1 yrs

Geoff Davis

TITLE
Director
AGE
70
TENURE
1.1 yrs

Lisa Haile

TITLE
Scientific Advisor

Daniel Miller

TITLE
Member of Scientific & Medical Advisory Board

Jeffrey Miller

TITLE
Scientific Advisor
TENURE
1.4 yrs

Pierre Tariot

TITLE
Scientific Advisor
TENURE
1.4 yrs

Daniel Vallera

TITLE
Scientific Advisor
TENURE
1.4 yrs

Roger Porter

TITLE
Scientific Advisor
TENURE
1.4 yrs

Peter Kiener

TITLE
Director
AGE
66
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • GT Biopharma insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. Feb 19 Sell Anthony Cataldo Individual 06. Feb 19 06. Feb 19 -800,000 €0.00 €-703
X
Management checks
We assess GT Biopharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. GT Biopharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Map
Description

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based off its proprietary technology platforms. The company develops immuno-oncology product candidates, including OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors; OXS-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate targeting CD33+ malignancies; OXS-C3550, a next-generation version of OXS-3550 containing a modified CD16 component; and OXS-1615, a single-chain fusion protein that targets epithelial tumors and CD133 positive solid tumors. It also develops central nervous system central nervous system, such as GTP-004, a fixed-dose combination tablet that has completed Phase I clinical trial for the treatment of the muscle weakness associated with myasthenia gravis; PainBrake, a patented formulation of carbamazepine to treat neuropathic pain; and GTP-011, a transdermal product for the prevention of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was founded in 1965 and is based in Westlake Village, California.

Details
Name: GT Biopharma, Inc.
GTBP
Exchange: ENXTPA
Founded: 1965
$18,853,258
50,900,000
Website: http://www.gtbiopharma.com
Address: GT Biopharma, Inc.
310 North Westlake Boulevard,
Suite 206,
Westlake Village,
California, 91362,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK GTBP Common Stock Pink Sheets LLC US USD 06. Jan 1971
LSE 0RU9 Common Stock London Stock Exchange GB EUR 06. Jan 1971
ENXTPA GTBP Common Stock Euronext Paris FR EUR 06. Jan 1971
Number of employees
Current staff
Staff numbers
5
GT Biopharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/23 20:41
End of day share price update: 2018/12/04 00:00
Last earnings filing: 2018/11/14
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.